Abbott Laboratories $ABT Shares Sold by Boston Partners

Boston Partners trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 99.0% during the second quarter, HoldingsChannel.com reports. The fund owned 30,092 shares of the healthcare product maker’s stock after selling 3,107,794 shares during the period. Boston Partners’ holdings in Abbott Laboratories were worth $4,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of ABT. J.W. Cole Advisors Inc. increased its stake in Abbott Laboratories by 22.0% in the second quarter. J.W. Cole Advisors Inc. now owns 43,528 shares of the healthcare product maker’s stock valued at $5,920,000 after purchasing an additional 7,859 shares during the period. Advisors Asset Management Inc. increased its position in Abbott Laboratories by 11.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 25,522 shares of the healthcare product maker’s stock valued at $3,471,000 after acquiring an additional 2,660 shares during the period. Southeast Asset Advisors LLC raised its stake in Abbott Laboratories by 21.0% during the 2nd quarter. Southeast Asset Advisors LLC now owns 13,764 shares of the healthcare product maker’s stock valued at $1,872,000 after acquiring an additional 2,390 shares during the last quarter. Columbia Bank lifted its position in Abbott Laboratories by 14.4% during the 2nd quarter. Columbia Bank now owns 14,038 shares of the healthcare product maker’s stock worth $1,872,000 after acquiring an additional 1,767 shares during the period. Finally, Laurel Wealth Advisors LLC grew its stake in shares of Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after purchasing an additional 6,011,891 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.3%

Shares of Abbott Laboratories stock opened at $128.90 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The business’s fifty day moving average is $129.40 and its two-hundred day moving average is $131.06. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market cap of $224.14 billion, a PE ratio of 16.15, a P/E/G ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. Abbott Laboratories’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter last year, the business earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th were paid a dividend of $0.59 per share. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Evercore ISI lowered their target price on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a report on Wednesday, October 15th. Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Mizuho lifted their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.